Wegovy Dosing Schedule: The Five-Step Titration

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide dosing and protocol hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, a patient named Karen in Fort Worth told her prescribing clinician she'd doubled up on her dose to "speed things along." She'd been on 0.5 mg for two weeks, felt fine, and figured jumping straight to 1.7 mg would get her to results faster. Within 48 hours she was vomiting every four hours and couldn't keep water down. Her clinician, an internal medicine physician who works with compounded semaglutide patients, talked her back to 0.5 mg and extended that step to six weeks. "The schedule isn't a suggestion," he told her. "It's the whole strategy."

He's right. And the Wegovy dosing schedule is more clinically grounded than most online discussions make it seem.

This guide sits inside the broader Compounded Semaglutide Dosing and Protocols cluster, which is part of the compounded semaglutide pillar guide.

The Five Steps, and Why There Are Exactly Five

The titration protocol used in the STEP-1 trial is the reference frame for essentially every semaglutide dosing schedule in clinical practice. Here's how it lays out:

Weeks 1 through 4: 0.25 mg once weekly
Weeks 5 through 8: 0.5 mg
Weeks 9 through 12: 1.0 mg
Weeks 13 through 16: 1.7 mg
Week 17 onward: 2.4 mg (maintenance dose)

Sixteen weeks of escalation before you reach the target dose. That sounds slow to patients who are eager to see movement on the scale, and it is slow by design. GLP-1 agonism slows gastric emptying, the mechanism behind most of the nausea and GI distress people associate with semaglutide. That effect doesn't flip on like a switch; it develops over weeks. The titration schedule gives the gut time to adjust at each plateau before the next increase. Patients who skip steps reliably report worse tolerability than those who don't. Karen's story isn't unusual. It's the norm.

For comparison, the Ozempic escalation (indicated for type 2 diabetes, not chronic weight management) is shorter and tops out lower: 0.25 mg for four weeks, then 0.5 mg, then 1.0 mg, with 2.0 mg available for glycemic control. The pharmacy-level supply situation in 2026 is more stable than the chaotic stretch of 2023 and 2024, but availability still shifts, and that influences which form a patient can access at any given time.

Where You Are in the Schedule Changes Everything

The question of Wegovy dosing schedule really comes down to three variables: where in the titration the patient currently sits, what the clinical goal is, and how tolerability has been running.

A patient at week six with mild nausea on 0.5 mg is in a completely different situation than someone at week sixteen who's been cruising at 1.7 mg for a full month without complaint. Same medication, same molecule, very different clinical conversations. This is why cookie-cutter advice from forums tends to be useless.

Compounded semaglutide uses the same active ingredient as Wegovy and Ozempic. The titration schedule in compounded programs is determined by the prescribing clinician and typically mirrors the Wegovy steps above, though doses are measured in milligrams rather than pre-filled pen units. Compounded semaglutide is not FDA-approved. The clinical evidence base for the molecule itself comes from the branded product trials. Compounded preparations have not been independently tested in randomized trials at the same scale.

The Evidence Behind the Numbers

The dosing framework described here traces directly to published clinical trials:

STEP-1 tested 2.4 mg weekly semaglutide against placebo over 68 weeks and reported a mean 14.9 percent weight loss from baseline in the active arm. That's the trial that established the five-step titration as standard.

STEP-3 layered a structured lifestyle intervention on top of the same protocol and produced higher mean weight loss, which tells you something important about what the medication can and can't do on its own.

STEP-4 documented what happens when you stop. Patients switched from active drug to placebo at week 20 experienced partial weight regain over the following 48 weeks. The chronic biology of weight regulation reasserts itself without pharmacologic support, the same way blood pressure drifts back up when you stop an antihypertensive.

SUSTAIN-6 and LEADER anchor the cardiovascular safety profile for the GLP-1 class. SELECT, completed in 2023, reported a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity without diabetes. That trial shifted the clinical conversation around GLP-1 therapy from "weight loss drug" to something with legitimate cardiometabolic utility.

How to Actually Give Yourself the Injection

Semaglutide is a subcutaneous injection, delivered into the abdomen, upper thigh, or upper arm. Rotate sites week to week to avoid local injection-site reactions. Let the medication sit at room temperature for fifteen to twenty minutes before injecting. After that, put it back in the fridge unless the pharmacy specifically says room-temperature storage is fine for a defined window.

The injection itself takes seconds. Patients consistently say the anticipation is worse than the needle. (It almost always is.) Pick a fixed weekday and a consistent time of day. This makes adherence easier and, just as importantly, helps you spot tolerability patterns. If you're always nauseated on Wednesdays and you inject on Tuesdays, that's a useful signal. If you inject at random, you're flying without instruments.

Three Situations That Warrant a Dose Adjustment

Not every side effect means something needs to change, but three patterns commonly trigger a clinical conversation:

1. GI symptoms that won't quit. If nausea, vomiting, or diarrhea persist for more than a week after a dose increase, holding the dose or stepping back is reasonable. Pushing through severe GI distress is not toughness; it's a setup for dehydration and poor adherence.

2. Weight loss that's too fast. This sounds like a good problem. It's not. A rate exceeding roughly 1.5 to 2 percent of body weight per week raises concerns about muscle loss and nutritional deficiency. When total caloric intake drops sharply, every calorie you eat carries more nutritional weight. Losing too fast while eating too little of the right things is a bad combination.

3. A stalled response at maintenance. After several months at the target dose, some patients plateau. The answer isn't always a higher dose. Sometimes it's a different intervention, whether that's dietary coaching, exercise programming, or a medication class switch. My honest take: the instinct to just go higher is almost always the wrong first move at a plateau.

What People Get Wrong

A few misconceptions show up constantly in patient questions about Wegovy dosing schedule:

"Compounded semaglutide is the same as Wegovy, just cheaper." The active ingredient is the same molecule. The regulatory status is not. Compounding pharmacies operate under a different framework with different oversight, and compounded preparations are not FDA-approved. That distinction matters for how the product is manufactured, tested, and monitored.

"Worse side effects mean it's working better." Trial data don't support this. In STEP-1 and STEP-3, patients with mild GI tolerability and patients with more pronounced symptoms both achieved meaningful weight loss. Suffering more doesn't earn you better results. It just means your body is having a harder time adjusting.

"The medication does the heavy lifting, and lifestyle is optional." STEP-3, which combined semaglutide with structured lifestyle intervention, outperformed STEP-1, which used medication alone. Lifestyle is additive. Period.

"If I stop, I'll go right back to where I started." STEP-4 showed partial regain, not a complete return to baseline, over 48 weeks off the drug. But the trajectory is clear: without ongoing pharmacologic support (or a serious lifestyle maintenance plan), weight trends back toward its regulated set point. This is how chronic conditions work. It's not a personal failure; it's physiology.

The Schedule Is a Starting Point, Not a Straitjacket

Here's the thing clinicians know that the internet doesn't always communicate well: the labeled Wegovy schedule describes the default approach, not the only appropriate one. Holding a dose for an extra cycle because GI symptoms haven't settled is standard practice. Extending the titration from sixteen weeks to twenty or twenty-two weeks is common and clinically defensible. Some patients never reach 2.4 mg and still achieve meaningful outcomes at 1.7 mg.

What matters more than the exact schedule is the quality of the clinical relationship. A program that supports honest conversation, responds to side effects with appropriate adjustments, and provides clear follow-up between refills will produce better outcomes than one with slick marketing and a thin clinical backbone.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Dosing and Protocols cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

What dose of compounded semaglutide is considered standard?

Compounded semaglutide protocols are written by the prescribing clinician and informed by the Wegovy escalation schedule used in STEP-1. The typical reference pattern is 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, with the rate of titration adjusted to tolerability. Compounded preparations are not FDA-approved and dosing is not standardized across pharmacies.

How does titration affect tolerability?

Slow titration is the single largest determinant of gastrointestinal tolerability in published semaglutide trials. The STEP-1 protocol used four-week steps specifically to allow gastric emptying changes to adapt gradually.

Can a clinician hold a dose without restarting titration?

Holding a current dose for an additional cycle to allow side effects to settle is a common clinical adjustment and does not require restarting the full titration schedule, although a multi-week gap may warrant stepping down.

Is the 2.4 mg dose required for meaningful weight loss?

Not necessarily. Some patients achieve clinically significant weight loss at 1.0 mg or 1.7 mg. The 2.4 mg target was what STEP-1 studied, and it produced the highest mean weight loss in that trial, but the right maintenance dose depends on individual response and tolerability.

Does the schedule change if I'm using compounded semaglutide instead of branded Wegovy?

The molecule is the same, so the titration logic applies equally. The key difference is that compounded semaglutide doses may be measured and dispensed differently (syringes rather than pre-filled pens), and the prescribing clinician sets the specific schedule. Compounded semaglutide is not FDA-approved.

What if I miss a weekly dose?

If fewer than five days have passed since the missed dose, take it as soon as you remember. If more than five days have passed, skip that dose and take the next one on your regular day. Missing multiple consecutive weeks may warrant stepping back to a lower dose, depending on clinician guidance.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.